CN101743308B - 用于药物用途的脂肪酶变体 - Google Patents

用于药物用途的脂肪酶变体 Download PDF

Info

Publication number
CN101743308B
CN101743308B CN200780051638.6A CN200780051638A CN101743308B CN 101743308 B CN101743308 B CN 101743308B CN 200780051638 A CN200780051638 A CN 200780051638A CN 101743308 B CN101743308 B CN 101743308B
Authority
CN
China
Prior art keywords
lipase
seq
enzyme
activity
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780051638.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN101743308A (zh
Inventor
阿伦·斯文德森
迈克尔·斯克乔伊特
戴比·亚弗
拉斯·L·H·克里斯滕森
西格恩·E·拉森
尼娜·伦丁
迈克尔·拉姆萨
彼得·C·格雷戈里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Novozymes Inc
Original Assignee
Solvay Pharmaceuticals GmbH
Novozymes AS
Novozymes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH, Novozymes AS, Novozymes Inc filed Critical Solvay Pharmaceuticals GmbH
Priority to CN201510504893.8A priority Critical patent/CN105112386A/zh
Publication of CN101743308A publication Critical patent/CN101743308A/zh
Application granted granted Critical
Publication of CN101743308B publication Critical patent/CN101743308B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN200780051638.6A 2006-12-21 2007-12-12 用于药物用途的脂肪酶变体 Active CN101743308B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510504893.8A CN105112386A (zh) 2006-12-21 2007-12-12 用于药物用途的脂肪酶变体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21
US60/871,196 2006-12-21
PCT/US2007/087168 WO2008079685A2 (en) 2006-12-21 2007-12-12 Lipase variants for pharmaceutical use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510504893.8A Division CN105112386A (zh) 2006-12-21 2007-12-12 用于药物用途的脂肪酶变体

Publications (2)

Publication Number Publication Date
CN101743308A CN101743308A (zh) 2010-06-16
CN101743308B true CN101743308B (zh) 2015-09-16

Family

ID=38043020

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510504893.8A Pending CN105112386A (zh) 2006-12-21 2007-12-12 用于药物用途的脂肪酶变体
CN200780051638.6A Active CN101743308B (zh) 2006-12-21 2007-12-12 用于药物用途的脂肪酶变体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510504893.8A Pending CN105112386A (zh) 2006-12-21 2007-12-12 用于药物用途的脂肪酶变体

Country Status (16)

Country Link
US (3) US8273348B2 (enExample)
EP (6) EP2455459B1 (enExample)
JP (1) JP5406040B2 (enExample)
KR (1) KR20090101930A (enExample)
CN (2) CN105112386A (enExample)
AR (1) AR064494A1 (enExample)
AU (1) AU2007337150A1 (enExample)
BR (1) BRPI0721103A2 (enExample)
CA (3) CA3081308C (enExample)
IL (1) IL198893A0 (enExample)
MX (1) MX2009006597A (enExample)
NO (1) NO20092729L (enExample)
RU (1) RU2009128067A (enExample)
TW (1) TW200829698A (enExample)
WO (1) WO2008079685A2 (enExample)
ZA (1) ZA200903598B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
JP5140586B2 (ja) 2005-07-29 2013-02-06 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 滅菌パンクレアチン粉末の製法
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
KR20090101930A (ko) 2006-12-21 2009-09-29 노보자임스 에이/에스 약학적 사용을 위한 리파아제 변형체
MX2010009457A (es) * 2008-02-29 2010-09-24 Procter & Gamble Composicion detergente que comprende lipasa.
CA2716692A1 (en) 2008-02-29 2009-09-03 Dsm Ip Assets B.V. Lipases with high specificity towards short chain fatty acids and uses thereof
CN101990573B (zh) * 2008-02-29 2014-01-22 诺维信公司 具有改进的稳定性的脂肪分解酶变体及编码该变体的多核苷酸
CN102652175B (zh) 2009-12-09 2016-02-10 宝洁公司 织物和家居护理产品
US20140147895A1 (en) 2011-07-22 2014-05-29 Novozymes A/S Processes for Pretreating Cellulosic Material and Improving Hydrolysis Thereof
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
CN104024393A (zh) 2011-12-29 2014-09-03 诺维信公司 具有脂肪酶变体的洗涤剂组合物
EP3696265B1 (en) * 2012-02-03 2025-03-19 Novozymes A/S Lipase variants and polynucleotides encoding same
CN107988181A (zh) * 2012-04-02 2018-05-04 诺维信公司 脂肪酶变体以及编码其的多核苷酸
EP3842531A1 (en) * 2012-10-12 2021-06-30 Danisco US Inc. Compositions and method comprising a lipolytic enzyme variant
RU2020101263A (ru) * 2013-05-14 2020-02-17 Новозимс А/С Моющие композиции
CN105555951A (zh) * 2013-07-19 2016-05-04 丹尼斯科美国公司 包含脂解酶变体的组合物和方法
CN107075489A (zh) * 2014-11-20 2017-08-18 诺维信公司 脂环酸芽孢杆菌变体以及编码它们的多核苷酸
MX388061B (es) * 2014-12-05 2025-03-19 Novozymes As Variantes de lipasa y polinucleotidos que las codifican.
EP3230442B1 (en) * 2014-12-09 2019-05-22 Novozymes A/S Lipase variants and polynucleotides encoding same
WO2016164596A2 (en) 2015-04-07 2016-10-13 Novozymes A/S Methods for selecting enzymes having lipase activity
WO2017001673A1 (en) * 2015-07-01 2017-01-05 Novozymes A/S Methods of reducing odor
WO2017005640A1 (en) * 2015-07-03 2017-01-12 Novozymes A/S Detergent compositions with improved stability in the presence of sulfites
EP3485008B1 (en) * 2016-07-18 2024-01-31 Novozymes A/S Lipase variants, polynucleotides encoding same and the use thereof
CN110462037A (zh) * 2017-01-30 2019-11-15 学校法人日本医科大学 腺相关病毒(aav)衣壳蛋白的突变体
EP3461892A3 (en) 2017-09-27 2019-06-12 The Procter & Gamble Company Detergent compositions comprising lipases
US11332725B2 (en) * 2017-09-27 2022-05-17 Novozymes A/S Lipase variants and microcapsule compositions comprising such lipase variants
WO2019154954A1 (en) * 2018-02-08 2019-08-15 Novozymes A/S Lipase variants and compositions thereof
WO2020037100A1 (en) * 2018-08-16 2020-02-20 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
WO2021260148A1 (en) * 2020-06-24 2021-12-30 Cilian Ag New lipase enzyme
US20240035005A1 (en) * 2020-10-29 2024-02-01 Novozymes A/S Lipase variants and compositions comprising such lipase variants
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用
PE20251535A1 (es) 2022-05-14 2025-06-05 Novozymes As Composiciones y metodos para prevenir, tratar, suprimir y/o eliminar infecciones e infestaciones fitopatogenas
CN119522274A (zh) * 2022-06-24 2025-02-25 诺维信公司 脂肪酶变体和包含这样的脂肪酶变体的组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018623A1 (en) * 1990-06-06 1991-12-12 Novo Nordisk A/S Recombinantly produced lipases for therapeutical treatment
CN1300319A (zh) * 1998-02-17 2001-06-20 诺维信公司 脂肪酶变体
CN1409760A (zh) * 1999-03-31 2003-04-09 诺维信公司 脂肪酶变体

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK46693D0 (enExample) * 1993-04-23 1993-04-23 Novo Nordisk As
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
EP0548228B1 (en) * 1990-09-13 1998-08-12 Novo Nordisk A/S Lipase variants
KR100237968B1 (ko) 1990-12-05 2000-01-15 한센 핀 베네드 변화된 에피토프를 지닌 단백질 및 그 제조방법
DK0585285T3 (da) 1991-05-01 1999-05-10 Novo Nordisk As Stabiliserede enzymer
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
WO1995009909A1 (en) 1993-10-04 1995-04-13 Novo Nordisk A/S An enzyme preparation comprising a modified enzyme
JP3553958B2 (ja) 1994-02-22 2004-08-11 ノボザイムス アクティーゼルスカブ 脂質分解酵素の変異体の製造方法
EP0793726A1 (en) 1994-11-24 1997-09-10 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
JPH10510516A (ja) 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ アレルゲン性を減らしたポリペプチド
WO1996023062A1 (en) 1995-01-26 1996-08-01 Novo Nordisk A/S Animal feed additives comprising xylanase
WO1997004079A1 (en) 1995-07-14 1997-02-06 Novo Nordisk A/S A modified enzyme with lipolytic activity
US6495357B1 (en) * 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
WO1997007202A1 (en) 1995-08-11 1997-02-27 Novo Nordisk A/S Novel lipolytic enzymes
CN1253585A (zh) 1997-01-10 2000-05-17 诺沃挪第克公司 一种用于皮肤护理的被修饰酶
CA2279986A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
EP1002064B1 (en) 1997-06-25 2007-10-10 Novozymes A/S A modified polypeptide
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
CN1323345A (zh) 1998-10-13 2001-11-21 诺沃奇梅兹有限公司 具有降低的免疫应答的修饰多肽
JP2002531067A (ja) 1998-10-30 2002-09-24 ノボザイムス アクティーゼルスカブ 低下したアレルゲン性を有するグリコシル化タンパク質
ATE263778T1 (de) 1998-10-30 2004-04-15 Novozymes As Niedrigallergene proteinvarianten
US7312062B2 (en) 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
EP1131416B1 (en) 1998-11-27 2009-09-02 Novozymes A/S Lipolytic enzyme variants
EP1162995B1 (de) * 1999-03-17 2003-06-04 Solvay Pharmaceuticals GmbH Enzyme zur behandlung von diabetes mellitus typ i
US6939702B1 (en) * 1999-03-31 2005-09-06 Novozymes A/S Lipase variant
WO2001058276A2 (en) 2000-02-08 2001-08-16 F Hoffmann-La Roche Ag Use of acid-stable proteases in animal feed
EP2258853B1 (en) 2000-04-28 2016-06-08 Novozymes A/S Lipolytic enzyme variant
EP1352057B1 (en) * 2001-01-10 2009-03-25 Novozymes A/S Lipolytic enzyme variant
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
CA2432329C (en) 2001-02-07 2012-04-10 Novozymes A/S Lipase variants
CA2467415C (en) * 2002-01-16 2014-03-11 Novozymes A/S Lipolytic enzyme variants and method for their production
WO2004069872A1 (en) 2003-02-06 2004-08-19 Novozymes A/S Human heavy chain antibody expression in filamentous fungi
DK2270139T3 (en) * 2003-05-09 2016-11-07 Novozymes As Lipolytic Enzyme Variants
WO2004111216A2 (en) 2003-06-19 2004-12-23 Novozymes A/S Phospholipase variants
US20060236414A1 (en) 2003-06-19 2006-10-19 Novozymes A/S Proteases and methods for producing them
AR047440A1 (es) 2004-01-21 2006-01-18 Novozymes As Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
AU2005295754B2 (en) 2004-10-14 2010-09-09 Eli Lilly And Co. Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
US20080138856A1 (en) 2005-02-10 2008-06-12 Novozymes A/S Enzymatic Enantioselective Ester or Amide Hydrolysis or Synthesis
NZ563777A (en) 2005-06-24 2010-08-27 Novozymes As Serine protease derived from Bacillus licheniformis optionally in combination with lipases and amylases for pharmaceutical use
RU2008102650A (ru) 2005-06-24 2009-07-27 Новозимс А/С (Dk) Амилазы для фармацевтического применения
WO2006136159A2 (en) * 2005-06-24 2006-12-28 Novozymes A/S Lipases for pharmaceutical use
WO2007080197A2 (en) * 2006-01-16 2007-07-19 Novozymes A/S Immobilised enzymes
EP1979456A2 (en) * 2006-01-23 2008-10-15 The Procter & Gamble Company A composition comprising a lipase and a bleach catalyst
DK2371949T3 (en) * 2006-01-23 2017-06-26 Novozymes As lipase variants
KR20090101930A (ko) * 2006-12-21 2009-09-29 노보자임스 에이/에스 약학적 사용을 위한 리파아제 변형체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018623A1 (en) * 1990-06-06 1991-12-12 Novo Nordisk A/S Recombinantly produced lipases for therapeutical treatment
CN1300319A (zh) * 1998-02-17 2001-06-20 诺维信公司 脂肪酶变体
CN1409760A (zh) * 1999-03-31 2003-04-09 诺维信公司 脂肪酶变体

Also Published As

Publication number Publication date
US9029115B2 (en) 2015-05-12
EP2455459A3 (en) 2013-04-24
AR064494A1 (es) 2009-04-08
WO2008079685A3 (en) 2008-11-06
US20100034797A1 (en) 2010-02-11
CA3081308C (en) 2024-02-20
ZA200903598B (en) 2010-04-28
RU2009128067A (ru) 2011-01-27
EP2455460A2 (en) 2012-05-23
EP2455462A2 (en) 2012-05-23
EP2455462A3 (en) 2013-05-29
BRPI0721103A2 (pt) 2014-03-04
CA2670643C (en) 2017-04-25
TW200829698A (en) 2008-07-16
US8273348B2 (en) 2012-09-25
NO20092729L (no) 2009-09-18
EP2455459B1 (en) 2016-03-16
MX2009006597A (es) 2009-07-02
CA2961041C (en) 2020-07-14
US20120308543A1 (en) 2012-12-06
US20150209414A1 (en) 2015-07-30
CA2961041A1 (en) 2008-07-03
EP2261328B1 (en) 2013-11-20
AU2007337150A1 (en) 2008-07-03
EP2455461A3 (en) 2013-05-29
EP2455462B1 (en) 2016-03-16
EP2099907A2 (en) 2009-09-16
EP2455461A2 (en) 2012-05-23
JP2010512795A (ja) 2010-04-30
KR20090101930A (ko) 2009-09-29
CA2670643A1 (en) 2008-07-03
WO2008079685A2 (en) 2008-07-03
CN101743308A (zh) 2010-06-16
JP5406040B2 (ja) 2014-02-05
EP2455461B1 (en) 2016-03-16
IL198893A0 (en) 2010-02-17
EP2261328A1 (en) 2010-12-15
US9539311B2 (en) 2017-01-10
CN105112386A (zh) 2015-12-02
CA3081308A1 (en) 2008-07-03
EP2455459A2 (en) 2012-05-23
EP2455460A3 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
CN101743308B (zh) 用于药物用途的脂肪酶变体
US20090047266A1 (en) Lipases for Pharmaceutical Use
KR20100092450A (ko) 약학적 사용을 위한 프로테아제 변이체
AU2013203500B2 (en) Lipase variants for pharmaceutical use
AU2013200626B2 (en) Lipase variants for pharmaceutical use
HK1141553A (en) Lipase variants for pharmaceutical use
HK1113174A (en) Lipases for pharmaceutical use
HK1145697A (en) Protease variants for pharmaceutical use
HK1117068A (en) Amylases for pharmaceutical use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1141553

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: NOVOZYMES BIOTECH INC.

Free format text: FORMER OWNER: NOVOZYMES BIOTECH INC. ABBOTT PRODUCTS, INC.

Effective date: 20120215

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Denmark bagsvaerd

Applicant after: NOVOZYMES A/S

Co-applicant after: NOVOZYMES, Inc.

Co-applicant after: Abbott Products Ltd.

Address before: Denmark bagsvaerd

Applicant before: NOVOZYMES A/S

Co-applicant before: NOVOZYMES, Inc.

Co-applicant before: Solvay Pharmaceuticals GmbH

TA01 Transfer of patent application right

Effective date of registration: 20120215

Address after: Denmark bagsvaerd

Applicant after: NOVOZYMES A/S

Co-applicant after: NOVOZYMES, Inc.

Address before: Denmark bagsvaerd

Applicant before: NOVOZYMES A/S

Co-applicant before: NOVOZYMES, Inc.

Co-applicant before: Abbott Products Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1141553

Country of ref document: HK